Pahl Kristy S, McLean Thomas W
Department of Pediatrics, Duke University School of Medicine, Durham.
Wake Forest School of Medicine, Winston-Salem, NC.
J Pediatr Hematol Oncol. 2022 Mar 1;44(2):31-39. doi: 10.1097/MPH.0000000000002384.
Infantile hemangiomas (IHs) are common vascular lesions which are benign but can cause significant functional and cosmetic morbidity. Since the fortuitous discovery of propranolol being effective to treat IH over a decade ago, the therapy and prognosis for children with IH have improved dramatically. Oral propranolol (as well as other oral beta-blockers and topical timolol) are safe and effective treatments, and have now supplanted other therapies. Making the correct diagnosis is crucial, because other vascular lesions can mimic IH. In addition, IH can be the first manifestation of an underlying syndrome. For IH requiring treatment, initiating treatment early is key to optimizing success. Therefore, early recognition and referral, if necessary, are important. Continued research on IH, both basic science and clinical, should result in continued advances.
婴儿血管瘤（IHs）是常见的血管病变，虽为良性，但可导致严重的功能和美容问题。自十多年前偶然发现普萘洛尔对治疗婴儿血管瘤有效以来，患有婴儿血管瘤的儿童的治疗和预后有了显著改善。口服普萘洛尔（以及其他口服β受体阻滞剂和局部用噻吗洛尔）是安全有效的治疗方法，现已取代了其他疗法。做出正确诊断至关重要，因为其他血管病变可能会模仿婴儿血管瘤。此外，婴儿血管瘤可能是潜在综合征的首发表现。对于需要治疗的婴儿血管瘤，尽早开始治疗是取得最佳疗效的关键。因此，必要时尽早识别并转诊很重要。对婴儿血管瘤的基础科学和临床研究的持续开展应会带来持续的进展。
